Ensysce completes enrollment in the PF614-MPAR-102 clinical study
The breakthrough therapy-designated medication utilizes MPAR technology to reduce opioid overdose risk while maintaining therapeutic efficacy at prescribed doses.
See the latest news and media coverage for Ensysce. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing abuse-deterrent pain therapies
ensysce.comLast updated
In short: Ensysce completed its PF614-MPAR-102 clinical study and finalized a $15 million NIDA grant for its overdose-protection technology.
The breakthrough therapy-designated medication utilizes MPAR technology to reduce opioid overdose risk while maintaining therapeutic efficacy at prescribed doses.
The deal adds a neuroplastogenic CRPS therapy with FDA orphan designation, $21.5M private placement, $17.1M Cy cash, and up to $38.6M on milestone.
The opioid reduces exposure above therapeutic thresholds, holds FDA Breakthrough Therapy designation, and addresses 80,000 annual U.S. overdose deaths with NIDA support.
The FDA recognized it as a substantial improvement over existing therapies for oral overdose protection. Ensysce has enrolled the first patient in Part 3 of the PF614-MPAR-102 study.
Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~SAN DIEGO, CA / ACCESS Newswire / / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company...
Ensysce Biosciences ( ($ENSC) ) just unveiled an update. On August 5, 2026, Ensysce Biosciences acquired Cy Biopharma, Inc. and entered into a Securities Purchase...
Redwire’s SpaceMD to fly 32 research units on SpaceX Starfall in 2028 · SpaceX says Terafab to be built in Texas with initial investment of...
Ensysce Biosciences, Inc (NASDAQ:ENSC) stock gained almost 100% with a strong session volume...
Track Ensysce and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Ensysce and other trending companies.